Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Graham Cooper barrels in as Geron CFO

This article was originally published in Clinica

Executive Summary

Geron Corporation has appointed Graham Cooper executive vice-president of finance and business development and chief financial officer. From 2006 to 2011, Mr Cooper served as senior vice-president, CFO and treasurer of Orexigen Therapeutics, where he was instrumental in growing the company from a venture-backed start-up into a sizeable public company. Geron recently put its stem cell assets up for sale, and dropped its clinical programme for GRNOPC1, a stem cell therapy for acute spinal cord injury that had been in a Phase I trial (, 15 November 2011). The company now plans to concentrate on its drugs imetelstat and GRN1005, which are in Phase II studies.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts